NCT04776889View on ClinicalTrials.gov

The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 15, 2019

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Prostate Cancer Metastatic
Interventions
DRUG

Rosuvastatin 20mg

Rosuvastatin 20mg/day for 6 months added to bilateral subcapsular orchiectomy

PROCEDURE

surgical castration

bilateral subcapsular orchiectomy

Trial Locations (1)

112796

National Cancer Institute, Cairo

All Listed Sponsors
lead

National Cancer Institute, Egypt

OTHER

NCT04776889 - The Prognosis of Lipid Reprogramming With Rosuvastatin, in Castrated Egyptian Prostate Cancer Patients | Biotech Hunter | Biotech Hunter